WAVE Life Sciences Ltd
WVE
View Detailed Chart
6.960USD
+0.160+2.35%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
1.08BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+2.35%
5 Days
-5.82%
1 Month
-28.69%
6 Months
-31.56%
Year to Date
-43.73%
1 Year
+21.89%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated：2025-09-17Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite strong stock market performance and technicals, the fundamentals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
15
analysts
Buy
Current Rating
19.800
Target Price
+190.32%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Wave Life Sciences Ltd. is a biotechnology company. The Company is focused on unlocking the potential of RNA medicines (oligonucleotides), or those targeting ribonucleic acid (RNA), to transform human health. Its RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing and RNA interference (RNAi), providing Company with capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. These programs include WVE-N531, WVE-006 and WVE-003. It is also building a pipeline of novel A-to-I RNA editing oligonucleotides (AIMers).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 2867.99% year-on-year.
Fairly Valued
The company’s latest PE is -8.51, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 156.69M shares, decreasing 1.02% quarter-over-quarter.
Held by Lee Ainslie
Star Investor Lee Ainslie holds 8.26M shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Wave Life Sciences Ltd. is a biotechnology company. The Company is focused on unlocking the potential of RNA medicines (oligonucleotides), or those targeting ribonucleic acid (RNA), to transform human health. Its RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing and RNA interference (RNAi), providing Company with capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. These programs include WVE-N531, WVE-006 and WVE-003. It is also building a pipeline of novel A-to-I RNA editing oligonucleotides (AIMers).
Ticker SymbolWVE
CompanyWAVE Life Sciences Ltd
CEODr. Paul B. Bolno, M.D.
Websitehttps://www.wavelifesciences.com/
Related Instruments
-0.35%
-4.12%
+3.22%
+1.87%
+0.75%
-1.87%
+0.72%
+6.30%
+0.83%
+2.41%
-0.11%
+0.02%
+2.31%
+0.70%
+0.93%
+1.86%
+5.59%
+3.22%
0.00%
+2.85%
